- Opinion
- [Reporter's View] Suspension of drug price cut
- by Kim, Jin-Gu May 8, 2023 05:41am
- The price of Forxiga, an SGLT-2 diabetes drug, remains unchanged despite the release of a generic version. AstraZeneca applied for suspension of drug price cut execution along with an administrative lawsuit, and the court accepted it. AstraZeneca cited the reason that Forxiga's indications include not only diabetes but also heart failure and
- Opinion
- [Reporter's View] Patent expired original
- by Lee, Tak-Sun May 3, 2023 05:38am
- For original drug patents that have expired, the upper limit is adjusted under the authority of the Ministry of Health and Welfare when a generic drug with the same product appears. Original drugs will be reduced to 70% of the previous price for one year, and from the second year onwards, the price will drop to the same 53.55% level as gener
- Opinion
- [Reporter's View] Rise of patients and concerns
- by Eo, Yun-Ho Apr 18, 2023 05:37am
- Medicine is a product with strong public goods characteristics. It is a means of curing human diseases and maintaining health. In Korea, national health insurance is also applied. Another fact is that it is the company that makes and sells it. The purpose is to make a profit. Pharmaceuticals are high-value-added products that can make a lo
- Opinion
- [Reporter's View] Preferential price for innovative drugs
- by Lee, Jeong-Hwan Apr 6, 2023 05:54am
- Second Vice Minister of Health and Welfare Park Min-soo promised the National Assembly that he would make a rule that gives preferential prices to medicines made by innovative pharmaceutical companies over other medicines. This is in the same context as Vice Minister Park Min-soo clearly expressed his will to improve the drug pricing system,
- Opinion
- [Reporter’s View] Accepting drugs used by very few patients
- by Eo, Yun-Ho Mar 30, 2023 05:41am
- It's the same 'cancer', but different. So how should we regard these new anticancer drugs that target only a very few among all patients that have the same type of cancer? The cancer types that we commonly refer to, such as liver cancer, stomach cancer, and lung cancer are just major categories used, and the specific condition of each pat
- Opinion
- [Reporter's view] The goal of global new drug development
- by Hwang, Jin-joon Mar 28, 2023 05:54am
- When the government announced the 'Third Five-Year Comprehensive Plan to Foster and Support the Pharmaceutical Bio Industry', it was emphasized that it would create three new blockbuster drugs that record global sales of more than 1 trillion won by 2030. For this purpose, strategic R&D investment was selected as a key task. In the development
- Opinion
- [Reporter's view] Tagrisso's first benefit
- by Mar 27, 2023 05:56am
- AstraZeneca's lung cancer drug Tagrisso has begun receiving benefits for first-line treatment. After 5 challenges, he passed the HIRA Cancer Disease Review Board. After adding the first treatment indication in December 2018, Tagrisso actively tried to expand benefits but was rejected by the review committee every time. The reason was that loo
- Opinion
- [Reporter's view]Vaccine self-sufficiency rate to 80%
- by Kim, Jin-Gu Mar 23, 2023 04:45am
- In 2013, 10 years ago, the Ministry of Health and Welfare distributed a press release. The plan is to foster the domestic vaccine industry and raise the self-sufficiency rate of the National Immunization Vaccine to 80% by 2020. At the time, among the 28 types of National Immunization Vaccines, only 8 types of vaccines were self-sufficient, b
- Opinion
- [Reporter's view] PVA improvement plan & domestic drugs
- by Lee, Tak-Sun Mar 21, 2023 05:58am
- There is also concern about the proposal for improving PVA through research service. Last year, researchers (Bae Seung -jin, Ewha Womans University, etc.), who studied PVA's performance evaluation and improvement plan, ordered the screening management of drugs with high financial impacts. As a result, the selection criteria for the usage typ
- Opinion
- [Reporter’s View] ‘The smart office system’s great, but…
- by Eo, Yun-Ho Mar 15, 2023 05:56am
- The smart office system has become an industry trend. The term, which originally refers to an IT-based office near a residential area that allows employees to work remotely from satellite offices rather than commute to an office downtown, is applied a bit differently in the pharmaceutical industry. Taking into account the characteristics
